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ABSTRACT 
Background: In heart failure (HF) patients, left ventricular mechanical dispersion (LVMD) 
reflects heterogeneous mechanical activation of the left ventricle. In HF patients, LVMD can 
be reduced after CRT. Whether lesser LVMD is associated with improved outcome is 
unknown.  
Objective: To relate LVMD to long-term prognosis in a large cohort of HF patients after 6 
months of cardiac resynchronization therapy (CRT). 
Methods: Clinical, echocardiographic and ventricular arrhythmia (VA) data were analyzed 
from an ongoing registry of HF recipients of CRT. Baseline (prior to CRT) and 6-month 
echocardiograms were evaluated. LVMD was calculated as the standard deviation of the time 
from onset of the QRS complex to the peak longitudinal strain in a 17-segment model. 
Patients were divided into two groups, according to the median LVMD (84 ms) at 6 months 
post-CRT.  
Results: Of 1,185 patients (mean age 65±10 years, 76% male), 343 (29%) died during a 
mean follow-up of 55±36 months. Baseline LVMD was not associated with all-cause 
mortality and VA at follow-up. In contrast, patients with less LVMD (≤84 ms) at 6 months 
post-CRT had lower event rates (VA and mortality) compared to those with LVMD >84 ms. 
On multivariable analysis, greater LVMD at 6 months after CRT was independently 
associated with an increased risk of mortality (hazard ratio, 1.002; P=0.037) and VA (hazard 
ratio, 1.003; P=0.026) . 
Conclusion: Larger LVMD at 6 months after CRT is independently associated with all-cause 
mortality and VA. LVMD may be valuable in identifying patients who remain at high 
mortality risk after CRT implantation. 
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is indicated in heart failure (HF) patients who 
remain symptomatic despite optimal medical therapy (New York Heart Association (NYHA) 
functional class II-III and ambulatory IV), with wide QRS complex (≥120 ms) and reduced 
left ventricular ejection fraction (LVEF ≤35%).1 CRT has been shown to improve symptoms, 
induce LV reverse remodeling, improve LVEF and reduce mitral regurgitation by 
resynchronizing the LV.1, 2 These favourable effects have been associated with a decreased 
risk of ventricular arrhythmias, and reduced mortality.3, 4  
LV mechanical dispersion (LVMD) is a novel, echocardiographic parameter based on speckle 
tracking echocardiography that measures the time dispersion to reach the peak systolic 
deformation in the different LV segments.5, 6 LVMD reflects mechanical heterogeneity, 
which has been related to ventricular arrhythmias in a number of cardiac diseases.5, 7-11  A 
reduction in LVMD after CRT is related to a decrease in ventricular arrhythmias.9  Whether 
reduced LVMD after CRT translates into superior outcome is unclear. Accordingly, the 
present study evaluated the relation between LVMD at 6 months after CRT implantation, and 
the prognosis of HF patients.  
 
METHODS 
Patient population and data collection 
HF patients who received CRT according to current guidelines and who completed clinical 
and echocardiographic follow-up at 6 months after CRT implantation were retrospectively 
evaluated.1 Various clinical, laboratory and imaging data were collected at baseline and 6 
months follow-up. Ischemic HF was defined by the presence of coronary artery disease, i.e. 
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evidence in previous medical records or from non-invasive or invasive investigations. The 
Dutch Central Committee on Human-related Research (CCMO) allows the use of anonymous 
data without prior approval of an institutional review board, provided that the data are 
acquired for routine patient care. All data used for the present study were acquired for clinical 
purposes and handled anonymously. 
Among the clinical variables, the quality of life, according to the Minnesota Living with 
Heart Failure Questionnaire, the 6-minute walking distance and the NYHA functional class 
were considered to define the severity of HF.12,13 Renal function was defined by the estimated 
glomerular filtration rate (eGFR), calculated according to the Modification of Diet in Renal 
Disease Study (MDRD) equation.14  The efficacy of CRT was analyzed as the percentage of 
patients receiving <98% and <90% of biventricular pacing, respectively.15 A significant 
burden of premature, ventricular contractions (PVC’s) was defined as >10000 per 24 hours.16, 
17 
Transthoracic echocardiography was performed in the left lateral decubitus position prior to 
and at 6 months after CRT implantation in all patients, utilizing a commercially available 
echocardiographic system (E9 or VIVID 7, General Electric Vingmed Ultrasound, 
Milwaukee, USA) equipped with 3.5 MHz or M5S transducers. As previously described,18 
M-mode, two-dimensional and Doppler data were acquired and digitally stored for off-line 
analysis (EchoPac 113, General Electric Vingmed Ultrasound, Milwaukee, USA).  
Speckle tracking echocardiography was used to measure LVMD at baseline and at 6 months 
after CRT implantation. LVMD was calculated as the standard deviation of the time from the 
onset of the QRS complex on the triggered ECG, to the peak longitudinal myocardial strain in 
a 17-segment LV model (Figure 1). The inter-observer and intra-observer variability of 
LVMD measurement were assessed calculating the intra-class correlation coefficient (ICC) 
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for both measures on 25 randomly selected patients. The ICC for inter-observer and intra-
observer variability of LVMD were 0.84 (95% CI: 0.64-0.93, P<0.001) and 0.93 (95% CI: 
0.85-0.97, P<0.001), respectively. 
Implantation of CRT 
The subclavian or cephalic veins were utilized to place the right atrial and ventricular leads in 
a standard fashion. Coronary sinus venography was performed (with a balloon catheter) to 
guide LV lead implantation. The LV pacing lead was introduced into the coronary sinus 
through an 8 Fr guiding catheter, and preferably positioned in a (postero-) lateral vein. 
Thereafter all the leads were connected to a dual-chamber, biventricular CRT-device. A CRT 
device with defibrillator function was implanted in most of the recipients. Patients were 
scheduled for regular follow-up at the HF outpatient clinic and to evaluate device function. 
The atrioventricular and inter-ventricular delays were empirically set at 120-140 ms and 0 ms 
respectively, while optimization of the CRT device was left at the discretion of the treating 
physician. 
 
Follow-up  
The clinical response to CRT was defined as improvement  ≥1 NYHA functional class at 6 
months of follow-up.19 LV reverse remodeling was defined as ≥15% reduction in the LV end-
systolic volume (LVESV) at 6 months of follow-up. Patients were followed-up for the 
occurrence of all-cause mortality, as well as the occurrence of ventricular arrhythmias 
(appropriate antitachycardia pacing and/or appropriate defibrillation by CRT-defibrillator). 
The follow-up started at 6 months when the clinical, electrocardiographic and 
echocardiographic responses were assessed. 
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Statistical analysis 
Continuous variables are expressed as means and standard deviations, and categorical data as 
numbers and percentages. Survival analysis was performed according to the Kaplan-Meier 
method for all-cause mortality as well as ventricular arrhythmias. Comparisons between 
groups were performed according to the log-rank test. A Cox proportional hazards model was 
used to investigate the association between LVMD at 6 months follow-up and all-cause 
mortality, as well as ventricular arrhythmias. To show hazard change across the range of 
LVMD, as a continuous variable, a spline curve was fit for LVMD versus mortality as well as 
versus ventricular arrhythmias, with overlayed confidence intervals. Subsequently, 
multivariate spline models were constructed, after adjusting for the following covariates: 
gender, body mass index, diabetes mellitus, etiology of heart failure, diuretics, hemoglobin, 
renal dysfunction, left ventricular reverse remodeling and clinical CRT response.  All 
analyses were performed with SPSS for Windows, version 23.0 (SPSS, Armonk, NY, USA) 
and R, version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). All statistical 
tests were two-sided. A P-value <0.05 was considered statistically significant.  
 
RESULTS 
Patient characteristics 
A total of 1,185 patients (mean age 65±10 years, 76% male) with analysable 
echocardiographic data to calculate LVMD at baseline and 6 months after CRT were 
included. Strain analysis was not feasible in 90 (8%) patients. Baseline characteristics of the 
patient population are presented in Table 1. The etiology of HF was ischemic in 60% of 
patients and the mean LVEF at 6 months after CRT was 33.4±9.8%. The median baseline 
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LVMD was 96.3 ms (interquartile range (IQR) 74.5 – 126.4 ms), which decreased to 84.1 ms 
(IQR 65.4 – 112.4 ms) after 6 months of CRT. The percentage of patients with biventricular 
pacing <98% was 37%, and the percentage of patients with biventricular pacing <90% was 
9%. The percentage of patients with >10000 premature ventricular complexes per 24 hours in 
our cohort, was 2.2%.  
 
Association between LVMD at baseline and 6 months follow-up and survival 
In total, 343 (29%) patients died during a mean follow-up of 55±36 months after the 6-month 
echocardiography. The patient population was dichotomized according to the median value of 
LVMD at baseline (96 ms). There were no differences in all-cause mortality rates between 
those patients with a greater (>96 ms) and a lesser (≤ 96 ms) LVMD at baseline (Log-rank 
test P=0.253). The patient population was subsequently dichotomized according to the 
median value of LVMD at 6 months (84 ms). Patients with lesser LVMD at 6 months (≤84 
ms) had significantly lower all-cause mortality compared with patients with more LVMD 
(>84 ms) (Log-rank test P<0.001; Figure 2). In patients with LVMD ≤84 ms at 6 months, the 
cumulative all-cause mortality rates were 13, 42 and 55% at 30, 90 and 120 months follow-
up, respectively. In contrast, in the group of patients with LVMD >84 ms, the cumulative 
event rates were 18, 54 and 65% for the same follow-up time points. 
To investigate the association between LVMD at 6 months and all-cause mortality, a Cox 
proportional hazards model was constructed with variables known to influence mortality of 
HF patients (Table 2). On multivariable analysis, LVMD at 6 months was independently 
associated with increased mortality (hazard ratio, 1.002; 95% confidence interval, 1.000-
1.005; P=0.037). To show hazard change across the range of LVMD, as a continuous 
variable, a spline curve was fit for LVMD versus mortality. For all-cause mortality, predicted 
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from the 6-month LVMD, the assumption of linearity was not violated (χ2, 4.4, P=0.12). 
There was an increase of hazards for LVMD between 50 ms and 130 ms, after which a 
plateau appeared. At higher 6-month LVMD values, there is a decrease of the hazards, 
although there are too few observations in this range to support a meaningful, clinical 
interpretation (also reflected in the wider confidence intervals at higher LVMD) (Figure 3A). 
When adjusted for multiple covariates, the assumption of linearity was also not violated (χ2, 
3.0, P=0.23), and the curve demonstrated a similar shape to the unadjusted model, with 
hazards increasing for LVMD between 50 and 130 ms, whereafter  plateau was noted (Figure 
3B).  
 
Association between LVMD at baseline and 6 months follow-up and ventricular 
arrhythmias 
After a mean follow-up of 55±36 months, 403 (34%) of patients experienced a ventricular 
arrhythmia for which appropriate device therapy was delivered. No difference in freedom 
from ventricular arrhythmias was seen between those patients with a greater (>96 ms) and a 
lesser (≤ 96 ms) LVMD at baseline (Log-rank test P=0.781).  Patients with lesser LVMD at 6 
months (≤84 ms) experienced greater freedom from ventricular arrhythmias, compared to 
those with more LVMD (>84 ms) (Log-rank test P<0.001; Figure 4). In patients with LVMD 
≤84 ms at 6 months, the cumulative rates for ventricular arrhythmia were 15, 55 and 77% at 
30, 90 and 120 months follow-up, respectively. In contrast, in those individuals with LVMD 
>84 ms, the cumulative event rates were 21, 66 and 84% for the identical time points. 
To investigate the association between LVMD at 6 months and all-cause mortality, a Cox 
proportional hazards model was constructed with variables known to influence the mortality 
of HF patients (Table 3). On multivariable analysis, LVMD at 6 months was independently 
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associated with ventricular arrhythmias (hazard ratio, 1.003; 95% confidence interval, 1.000-
1.005; P=0.026). To show hazard change for ventricular arrhythmias across the range of 
LVMD as a continuous variable, a spline curve was fit for LVMD versus ventricular 
arrhythmias. For ventricular arrhythmias, predicted from the 6-month LVMD, the assumption 
of linearity was not violated (χ2, 6.0, P=0.06). There was an increase of hazards for LVMD 
between 50 ms and 130 ms, after which a plateau appeared. At higher 6-month LVMD 
values, there is a decrease of the hazards, although there are too few observations in this 
range to support a meaningful, clinical interpretation (also reflected in the wider confidence 
intervals at higher LVMD) (Figure 5A). When adjusted for multiple covariates, the 
assumption of linearity was also not violated (χ2, 1.2, P=0.55), and the curve demonstrated a 
similar shape to the unadjusted model, with hazards increasing for LVMD between 50 and 
130 ms, whereafter  plateau was noted (Figure 5B).  
 
DISCUSSION 
Patients with HF with greater LVMD at 6 months after receiving a CRT device, experienced 
a worse long-term outcome and more frequent ventricular arrhythmias, compared to patients 
with lesser LVMD. Additionally, the association between LVMD and mortality, as well as 
ventricular arrhythmias was independent of the occurrence of LV reverse remodeling at 6 
months. 
 
Role of LVMD in diagnosis and risk-stratification 
LVMD has been proposed as a marker of electromechanical heterogeneity of the left 
ventricle and is calculated as the standard deviation of the time from the onset of the QRS 
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complex to the peak longitudinal myocardial strain (obtained with two-dimensional speckle 
tracking echocardiography) in a 16- or17-segment LV model.5, 6 LVMD has been utilized in 
the diagnosis and risk-stratification of various cardiac disorders.5, 6, 8-11, 20-22  In post-infarct 
patients, LVMD has shown incremental value over LVEF to predict ventricular 
arrhythmias.22  
Similarly, LVMD discriminated between post-infarct patients with and without ventricular 
arrhythmias in a prospective study.5 In addition, LVMD has been associated with ventricular 
arrhythmias in HF patients with  ischemic and non-ischemic etiologies.8 A greater LVMD, 6 
months after CRT, has been demonstrated in recipients with ventricular arrhythmias at 
follow-up, compared to those without arrhythmias.9 Our data support this observation, with 
more frequent ventricular arrhythmias documented in individuals with greater LVMD after 
CRT.  However, the association between residual LVMD after CRT and all-cause mortality 
has not been evaluated.  
 
LVMD and outcome after CRT 
The main finding of this study is that LVMD after 6 months of CRT is independently 
associated with long-term outcome. Long-term outcome after CRT is influenced by a number 
of baseline characteristics, i.e. male gender, body mass index, diabetes mellitus, hemoglobin 
and impaired renal function.23-26 It is also well-established that LV reverse remodeling, as 
well as the extent thereof, impacts on long-term prognosis.27, 28 In the Resynchronization 
Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial, a ≥15% 
decrease in the indexed LVESV was an independent predictor of outcome.29 In contrast, 
although the clinical response to CRT was associated with better outcome, it was not 
independently associated with all-cause mortality in a study of 679 patients.30  
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Both LVMD and LV reverse remodeling after CRT are therefore more firmly linked to 
improved survival than a clinical response. A lesser LVMD likely reflects restoration of a 
more homogenous pattern of LV electromechanical activation by CRT, which accompanies 
LV reverse remodeling. Apical rocking, another surrogate of heterogenous LV activation, has 
demonstrated incremental value over LV reverse remodeling to predict mortality after CRT 
(hazard ratio 0.405; 95% confidence interval 0.283-0.579; P<0.0001).31 In addition, 
correction of apical rocking by CRT translated into lower all-cause mortality. Our results 
provide further support to the association of reestablishment of a more coordinated pattern of 
LV contraction and improved outcome after CRT. 
In a recent meta-analysis, including 3,667 patients, the risk of ventricular arrhythmias was 
found to be significantly lower in CRT responders (i.e. in whom LV remodeling has taken 
place) than in non-responders (odds ratio 0.436; 95% confidence interval 0.323-0.589; 
P<0.05).32 LV remodeling is therefore strongly related to both the risk of ventricular 
arrhythmias and outcome after CRT. In light of the connection between restoration of 
coordinated LV contraction (reflected by LVMD) and LV remodeling, the presence of more 
frequent ventricular arrhythmias in patients with a greater LVMD after 6 months of CRT, is 
consistent with ventricular arrhythmia burden as the cause of increased mortality in this 
group. 
The present study shows that LVMD after 6 months of CRT was significantly associated with 
long-term outcome independently of clinical response and LV reverse remodeling. Greater 
LVMD may thus identify a subgroup of patients who remain at high risk of mortality despite 
CRT. Such patients are candidates for close follow-up, as well as interventions which may 
modify their outcome, e.g. optimization of device programming, adjustment of 
pharmacotherapy and eventually mechanical LV support or cardiac transplantation. 
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Study limitations 
This was a retrospective, single-center study and included patients who completed the 6 
months follow-up echocardiographic evaluation. Therefore, there may be a selection bias, 
since LVMD could not be measured in patients who deceased during the first 6 months after 
CRT implantation. The mode of death was not systematically available. The measurements of 
LVMD are not vendor independent and the cut-off value of LVMD provided in this study 
may not be generalizable to other patients in whom LVMD was measured with different 
software. 
 
CONCLUSIONS 
LVMD after 6 months of CRT is independently associated with all-cause mortality and 
ventricular arrhythmias, and may therefore be valuable in identifying patients who remain at 
high risk after CRT implantation. 
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Table 1. Patient characteristics at baseline.  1 
 N=1,185 
Age (years) 65 ± 10 
Gender male, n (%) 904 (76) 
Ischemic aetiology, n (%) 712 (60) 
Heart rhythm at baseline, n (%) 
- Sinus rhythm  
- Paced rhythm 
- Atrial fibrillation  
 
867 (73) 
192 (16) 
126 (11) 
NYHA functional class, n (%) 
- I 
- II 
- III 
- IV 
 
57 (5) 
318 (27) 
733 (62) 
77 (6) 
6 MWT (m) 331 ± 121 
QoL score 32 ± 19 
Diabetes n (%) 253 (21) 
eGFR <60 ml/min/1.73 m2, n (%) 466 (39) 
LVEF (%) 27 ± 8 
LVEDV (ml) 203 ± 76 
LVESV (ml) 
LVMD (ms) 
150 ± 65 
96.3 ms (74.5 – 126.4) 
Values are mean ± standard deviation. eGFR: estimated glomerular filtration 2 
rate; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-3 
diastolic volume; LVESV: left ventricular end-systolic volume; LVMD: left 4 
ventricular mechanical dispersion; 6 MWT: six-minute walk test; NYHA: 5 
New York Heart Association class; QoL: quality of life  6 
Table 2. Uni- and multivariate Cox proportional hazards models for all-cause mortality. 7 
 Univariate analysis Multivariate analysis 
Variable HR  95% CI P-value HR  95% CI P-value 
LVMD at 6 months (ms) 1.004 1.002-1.006 <0.001 1.002 1.000-1.005 0.037 
Age at implant (years) 1.040 1.029-1.050 <0.001 1.030 1.019-1.041 <0.001 
Male gender 1.482 1.164-1.887 0.001 1.495 1.157-1.933 0.002 
Body mass index (kg/m2) 0.969 0.947-0.992 0.008 0.960 0.936-0.985 0.002 
Diabetes mellitus 1.649 1.329-2.046 <0.001 1.470 1.165-1.854 0.001 
Ischemic etiology of heart failure 1.547 1.265-1.893 <0.001 1.184 0.950-1.475 0.133 
Diuretics 1.751 1.325-2.313 <0.001 1.445 1.080-1.933 0.013 
Hemoglobin (g/dL) 0.806 0.731-0.890 <0.001 0.935 0.842-1.039 0.212 
Renal dysfunction (eGFR <60 ml/min/1.73 m2) 2.546 2.105-3.080 <0.001 1.983 1.612-2.439 <0.001 
LV reverse remodeling 0.537 0.380-0.759 <0.001 0.628 0.514-0.767 <0.001 
Clinical response  0.839 0.694-1.013 0.068 0.921 0.756-1.121 0.412 
 8 
CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; LVMD: left ventricular mechanical dispersion 9 
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Table 3. Uni- and multivariate Cox proportional hazards models for ventricular arrhythmias. 11 
 Univariate analysis Multivariate analysis 
Variable HR  95% CI P-value HR  95% CI P-value 
LVMD at 6 months (ms) 1.003 1.001-1.006 0.006 1.003 1.000-1.005 0.026 
Age at implant (years) 1.020 1.009-1.030 <0.001 1.018 1.008-1.030 0.001 
Male gender 1.704 1.305-2.225 0.001 1.723 1.306-2.273 <0.001 
Body mass index (kg/m2) 0.999 0.976-1.023 0.957 - - - 
Diabetes mellitus 1.243 0.967-1.596 0.089 1.176 0.910-1.520 0.216 
Ischemic etiology of heart failure 1.339 1.089-1.648 0.006 1.046 0.839-1.305 0.688 
Diuretics 1.126 0.873-1.451 0.361 - - - 
Hemoglobin (g/dL) 0.975 0.874-1.087 0.646 - - - 
Renal dysfunction (eGFR <60 ml/min/1.73 m2) 1.334 1.086-1.639 0.006 1.259 1.011-1.567 0.040 
LV reverse remodeling 0.672 0.551-0.821 <0.001 0.704 0.569-0.872 0.001 
Clinical response  0.759 0.621-0.928 0.007 0.832 0.675-1.026 0.086 
 12 
CI: confidence interval; eGFR: estimated glomerular filtration rate; HR: hazard ratio; LVMD: left ventricular mechanical dispersion 13 
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 14 
Figure 1: Assessment of left ventricular mechanical dispersion with two-dimensional 15 
speckle tracking echocardiography – left ventricular mechanical dispersion was calculated 16 
as the standard deviation of the time from the onset of the QRS complex on the ECG, to the 17 
peak longitudinal strain in 17 segments of the left ventricle. The segmental time to peak 18 
longitudinal strain data are presented in a color-coded, bull’s eye plot with the earliest 19 
segments presented in green and the most delayed segments in red. LVMD: left ventricular 20 
mechanical dispersion 21 
 22 
 23 
 24 
   
 
23 
 
 25 
Figure 2:  Kaplan-Meier curves for all-cause mortality - Time to all-cause mortality in 26 
patients with left ventricular mechanical dispersion ≤84 ms and >84 ms after 6 months of 27 
cardiac resynchronization therapy. LVMD: left ventricular mechanical dispersion 28 
 29 
 30 
 31 
 32 
 33 
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 35 
Figure 3: Spline curves for LVMD versus all-cause mortality. Predicted mortality across a 36 
range of left ventricular mechanical dispersion (LVMD), plotted as a fitted spline model on a 37 
log-hazard scale, with overlayed confidence intervals. The unadjusted model is shown in 38 
panel A, and the adjusted model in panel B. Ln: logarithm, HR: hazard ratio 39 
 40 
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 41 
Figure 4:  Kaplan-Meier curves for freedom from ventricular arrhythmias – Ventricular 42 
arrhythmia-free survival in patients with left ventricular mechanical dispersion ≤84 ms and 43 
>84 ms after 6 months of cardiac resynchronization therapy. LVMD: left ventricular 44 
mechanical dispersion 45 
 46 
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 48 
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 51 
Figure 5: Spline curves for LVMD versus ventricular arrhythmias. Predicted occurrence 52 
of ventricular arrhythmias across a range of left ventricular mechanical dispersion (LVMD), 53 
plotted as a fitted spline model on a log-hazard scale with overlayed confidence intervals.  54 
The unadjusted model is shown in panel A, and the adjusted model in panel B. Ln: logarithm, 55 
HR: hazard ratio 56 
 57 
